Conclusions & Recommendations
16.6.1 - WASH Upgrades for Health in Amhara study (WUHA)
Conclusion/Recommendation:
TEC welcomes the expression of interest from the WUHA study team and looks forward to receiving suggestions on how the study can be enhanced with the addition of targeted antibiotic when the study communities return to the standard of care.
Action:
ITI continues to work with our colleagues at UCSF, awaiting the study results.
TEC 16
2017
research
16.7.1 - Chad
Conclusion/Recommendation:
The TEC recommends to the national program to conduct surveys in Salal, Mandelia, Bardai, and Nokou and invites a mid-year request if warranted.
Action:
TEC recommendation was shared with MOH and OPC. They are working together to determine when it will be possible to access these areas, given security concerns.
TEC 16
2017
Africa - West
Chad
suspected endemic
16.8.1 - Côte d'Ivoire
Conclusion/Recommendation:
The TEC recommends that the MOH consider additional baseline mapping surveys and identify additional implementation/funding partners.
Action:
TEC recommendation was shared with MOH and MOH are working with FHI 360 to identify and secure funding for additional baseline mapping surveys and implementation support.
TEC 16
2017
Africa - West
Côte d'Ivoire
suspected endemic
16.9.1 - Niger
Conclusion/Recommendation:
It is not the policy of ITI, TEC, USAID, or WHO to insist that Zithromax® distribution be integrated with preventive chemotherapy for other NTDs. In order to avoid threatening the success of the trachoma program, the TEC recommends to the Niger MOH and its partners that the trachoma program continues with Zithromax® distribution on schedule and not delay treatments while awaiting other NTD program drugs. The TEC further recommends to the Niger MOH and partners to ensure they budget adequate funding to distribute Zithromax® on time.
Action:
This has been shared with the MOH, implementing partner (HKI), and funding partner; all
are supportive of separate MDAs going forward and integrating where and when it makes
sense. This was also shared with the other donation and funding partners via the Regional
Program Review Group (RPRG) and ESPEN.
TEC 16
2017
Africa - West
Niger
15.1.1 - General Recommendations to ITI
Conclusion/Recommendation:
TEC recommends to ITI to combine the current Reserve categories R2 & R3 into a single Reserve category (R2) for districts pending impact surveys
Action:
Done
TEC 15
2016
TEC meeting management, Zithromax® donation criteria
15.1.10 - General Recommendations to ITI
Conclusion/Recommendation:
TEC 16 will be held in Atlanta, GA, USA on June 6-8, 2017
Action:
No action required
TEC 15
2016
TEC meeting management
15.1.11 - General Recommendations to ITI
Conclusion/Recommendation:
TEC 17 will be held in Malawi on November 27-29, 2017 (pending confirmation from the Malawi MOH)
Action:
No action required
TEC 15
2016
TEC meeting management
15.1.2 - General Recommendations to ITI
Conclusion/Recommendation:
TEC recommends to ITI that they should modify the Supply & Demand forecast chart to include inventory already produced and expected in-country inventory
Action:
Done
TEC 15
2016
supply chain, TEC meeting management
15.1.3 - General Recommendations to ITI
Conclusion/Recommendation:
TEC recommends to ITI that one round of Zithromax® be approved for the entire population of districts presenting TF1-9 5-9%; and, if the baseline TF1-9 was >10%, an additional round Zithromax® can be put into Reserve (R2) for the following year
Action:
Done
TEC 15
2016
Zithromax® donation criteria
15.1.4 - General Recommendations to ITI
Conclusion/Recommendation:
TEC recommends to ITI to document variability in impact survey results to further understand what happens in the end game. ITI should share lessons learned with country programs to assist them in interpreting their own results, anticipating and addressing challenges, and to facilitate achievement of the GET 2020 goals
Action:
Analysis planned and countries are being given guidance as needed
TEC 15
2016
end game, persistence, recommendations for ITI management